I averaged down from $20 to about $10 last week. The cash value of the shares is a little over $1 now. They have about 6 drugs in the pipeline now, 3-4 from the old company MHAN, 2 more from the 2010 merger (one is a great B-12 based product for tremors IIRC), and the new one from the recent R/M. Weise owns and controls about 50% of the common IIRC, and for him to step in buy at $2.25 was the signal I was waiting for to average down.
I think this one has an easy ride back to $5 to $6 once they start a road show promo for investors. They may even get it back to $10, which would be a $200 million dollar market cap, but that may be pushing it at this point in time. My plan is to average down to about $3-4, and try to sell at $5 to $6 down the road. I don't think they will have too much trouble walking it back up to $5. When they walk it back up, is another matter.
Market Data 
Markets 
AI
